The initiative aims to transform and improve how clinical trials are conducted in the field of rare diseases.

The charitable initiative will allocate all funds to research on pediatric nervous system tumors carried out at the Vall d’Hebron Research Institute

The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

The donation will support a project investigating new therapeutic approaches in pediatric brain tumors

The €15,000 donation will boost research into this very rare type of childhood cancer.

The association has donated €15,088 to the Childhood Cancer and Blood Disorders group at VHIR to improve the treatment of rhabdomyosarcoma.

The Iris Association has made a €14,499 donation to the Childhood Cancer and Hematological Diseases Group at the Vall d’Hebron Research Institute (VHIR).

The funds raised will contribute to ensuring the continuity of the pediatric brain tumor research line developed by the Vall d’Hebron research teams.

2025 has been an active year with the participation of RADeep members at the Data Access Committee at Vall d’Hebron and the presentation of abstracts at the 67th ASH Annual Meeting and Exposition.

Since 2019, Pulseras Candela has been collaborating with the Childhood Cancer and Hematological Diseases group at VHIR on the project “New Therapeutic Approaches for the Treatment of Pediatric Ependymoma.”

The donation will boost several lines of research to advance liquid biopsy in pediatric sarcomas and brain tumors.

The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

The study analyzes the impact of COVID-19 on people with rare red blood cell disorders, identifying risk factors for severe forms of the disease.

The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.

The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.

During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).

Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.

The funds will strengthen research lines focused on nervous system tumors.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.

The Vall d’Hebron Institute of Research’s Paediatric Cancer and Hematological Diseases Research Group Achieves Promising Results for Acute Graft-Versus-Host Disease.

The study, which provides guidelines for the clinical management of these patients, reveals that only children with a recent stem cell transplant or with other additional diseases have a higher risk of complications from COVID-19.